CTRI/2023/08/056549招募中Unknown
A Post approval observational study to assess safety and effectiveness of oral digestive ENZYME tablets in Functional Dyspepsia (UNIENZYME-FD). - NI
试验速览
- 阶段
- Unknown
- 状态
- 招募中
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
入选标准
- •All patients must meet all of the following criteria for enrollment in the study:
- •1. Male or female patients 18 to 60 years
- •2. Clinical cases of Functional Dsypepsia that fulfils Rome IV criteria with persistent symptoms of Indigestion, Abdominal fullness, Satiety on alternate days of the week for at least 4 weeks
- •3. Patients may have failed to adequately respond to antisecretory therapy (PPi) or H. pylori therapy involving initial or sequential therapy of PPi +Amoxicillin+ Clarithromycin/Metronidazole for cases with prior UBT
排除标准
- 未提供
研究者
相似试验
尚未招募
4 期
To assess safety and effectiveness of Sitagliptin, Glimepiride, and Metformin for diabetes patients in India.CTRI/2024/03/064004Torrent Pharmaceuticals Ltd
招募中
不适用
An observational study to evaluate the safety and efficacy of MegaDerm Soft in patients who underwent breast reconstruction using the MegaDerm soft.KCT0007432Soon Chun Hyang University Hospital Bucheon60
招募中
4 期
An observational study to evaluate the safety and efficacy of FOLFIRI / FOLFOX plus Cetuximab as first-line therapy inpatients with KRAS wild-type metastatic Colorectal cancerCTRI/2010/091/000161Merck Specialities Pvt Limited5th Floor , Shivsagar EstateDr. Annie Besant RoadMumbai 400018100
尚未招募
Unknown
An observational study to evaluate the safety and efficacy of lenvatinib plus pembrolizumab combination therapy for advanced or recurrent uterine cancer after use of platinum-based drugs(GOGO-EM4)JPRN-UMIN000049997Gynecologic Oncology Group of Osaka(GOGO)100
尚未招募
4 期
Prospective Observational Study of Once-Daily Tamcontin® Tablet (Continus® Controlled release tablet of Tamsulosin Hydrochloride, 0.4 mg) in the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia (BPH) in the Routine Clinical PracticeCTRI/2012/11/003151ModiMundiPharma Pvt Ltd100